ScienceAbroad is a non profit organization. We are a global community of Israeli Scientists Abroad. We have 22 branches worldwide operated entirely by volunteers. We create a dynamic network for Israeli Scientists, providing valuable tools & connections.
ScienceAbroad a nonprofit organization strengthens research and industry in Israel by maintaining contact with talented Israeli scientists, researcher, physicians and entrepreneurs living around the globe. We are an ever-changing, vibrant community, benefitting 3 circles: internally among Israeli scientists, the local community within which they are currently operating, and the State of Israel. Our community promotes Israeli scientific achievement, bolsters the Israeli identity of scientists living overseas and helps to facilitate the return of great minds to Israel.
Dr. Shmulik Hess
Position: Founder & Chairman of the Executive Board
Dr. Shmulik Hess is the CEO of Valin Technologies Ltd. and a Board member of Vanir Pty. Ltd. Shmuel received his PhD in Pharmacology and Pharmaceutical Science from The Hebrew University of Jerusalem, and was a research fellow at the Harvard MIT Division of Health Science and Technology, Cambridge, Massachusetts. Prior to joining Valin Technologies, Shmuel co-founded and was CEO of Active Px, a biotechnology startup involved in the development of available oral peptidic drugs for the treatment of pain and metabolic disease. Shmuel served as a consultant for Scigen’s global operations. He has vast experience with peptide and protein PK & PD, as well as immunobiology and tissue engineering. Under his tenure, Valin has successfully developed recombinant human insulin and insulin analogs, recombinant human coagulation Factor VIIa, and has initiated new innovative projects in the field of therapeutic biologics. Shmuel holds three patents and has published several publications in scientific journals.
Dr. Gil Blander
Position: Founder & Executive Board Member
Dr. Gil Blander received his PhD in biology from the Weizmann Institute of Science (in Prof. Moshe Oren’s Lab), and undertook postgraduate research on aging at MIT (in Prof. Lenny Guarente's Lab). An expert in nutrition, biomarker analytics, athletic performance, biochemistry, and aging research, Gil holds numerous patents and has published peer-reviewed articles in these fields. Gil is the Founder and CSO of InsideTracker, a personalized health and performance analytics company created by a team of scientists, physicians, nutritionists and exercise physiologists from MIT, Harvard, and Tufts University. The InsideTracker platform tracks and analyzes key biochemical and physiological markers, then applies sophisticated algorithms and large scientific databases to determine personalized optimal zones for each marker. InsideTracker’s expert system offers science-driven nutrition and lifestyle interventions, which empower people to optimize their markers. When optimized, marker levels have been scientifically proven to increase vitality, improve athletic performance, and extend life. In 2006, Gil co-founded BioAbroad together with Dr. Shmulik Hess and Rami Lotem. Gil led the organization in 2011-2014 and is currently a member of its BOD.
Dr. Dan Gincel
Position: Executive Board Member
In his dual roles as VP for University Partnerships at the Maryland Technology Development Corporation (TEDCO) and Executive Director of the Maryland Stem Cell Research Fund, Dr. Dan Gincel oversees programs on university research, tech transfer, and the commercialization and innovation that contribute to economic growth in Maryland. His experience inside and beyond the lab has driven his proven leadership and made him a champion of university research and development. Dan is dedicated to boosting the research capacity for Maryland scientists, supporting cutting-edge technology development, and ultimately developing cures for debilitating diseases. Dan received his BSc and PhD in Biochemistry and Neuroscience from the Ben-Gurion University of the Negev in Israel and undertook postdoctoral research at the Johns Hopkins University in the US.
Mr. Sagi Balasha
Position: Executive Board Member
Sagi Balasha served as the National CEO (2011-2015) of the Israeli-American Council (IAC), an umbrella organization for the Israeli-American community in the US. Under his tenure, the organization went from a local operation with a single office and seven employees, to a national operation with seven offices and 80 employees in major cities around the US. Sagi metamorphosed the IAC into the premier organization in the American Jewish landscape, and today engages close to 200,000 people.
In October 2015, Sagi and his family returned to Israel. Today Sagi is business development and project management consultant for an array of organizations. His major focus is on the development of Israel-based projects in the cyber field and fighting the de-legitimization and hatred campaign against Israel, in collaboration with a number of American philanthropists and organizations. Sagi is also the current CEO of the Israel Free Loan Association (IFLA).
Prior to his position at the IAC, Sagi was the VP of Finance and Development at Beit Hatfutsot (2006-2011) where he headed a financial recovery plan that served to restore and renew the organization from a state of major deficit – increasing the museum’s budget, space and number of visitors by more than 100%. Prior to this (2001-2006), Sagi was the Department Manager and later Department Director of Israel’s Ministry of Finance Budgets Department, where he oversaw 20% of the government’s budget and was involved in major structural changes and reforms.
Sagi has a BA with Honors in Economics and Geography from Ben-Gurion University of the Negev and earned his MA at The Hebrew University of Jerusalem.
Prof. Shulamit Kazav
Position: Executive Board Member
Associate Professor, Faculty of Medicine, The Hebrew University of Jerusalem.
Prof. Shulamit Katzav is the Bernard L. and Mary T. Sachs Professor of Cancer Studies. She earned her PhD at the Weizmann Institute of Science and undertook her post-doctoral research at the National Cancer Institute in Frederick, MD. Shulamit was a visiting scientist at St. Jude Children's Research Hospital in Memphis, Tennessee and an Associate Professor at McGill University in Montreal, Canada. Since 1995, Shulamit has been a member of the Institute of Medical Research Israel-Canada (IMRIC) at The Hebrew University of Jerusalem, Israel.
Shulamit served as the Chairs of the Research Committee of the Faculty of Medicine, Search Committee for the recruitment of young academic members ("Vaadat Sinun"), and the Department of Development Biology and Cancer Research at the Faculty of Medicine, Hebrew University. She is currently charged with implementing a bold and innovative new curriculum at the Hebrew University Medical School.
Shulamit’s lab focuses on the link between signal transduction and cancer, investigating a signal transducer protein, Vav, which is involved in coupling extracellular events to alterations in gene expression in the hematopoietic system. Shulamit discovered Vav when she tested DNA from five esophageal carcinomas for transforming activity. This newly identified gene represented the sixth transforming gene (oncogene) detected in the laboratory and it was designated Vav, the sixth letter of the Hebrew alphabet. She was recently the first scientist to demonstrate that Vav plays a major role as an oncogene in human cancers such as neuroblastoma, breast and lung. Vav was also shown to be integral to the development of pancreatic cancer. This indicates that Vav can be a promising target protein in anti-tumor therapy.
Prof. Gadi Schuster
Prof. Gadi Schuster is a member of the Technion’s Faculty of Biology. The incumbent of the Henry Goldberg Academic Chair in Science, Gadi focuses his research on the control of gene expression during development in micro-organisms, plants and animals. More specifically, he is researching the molecular mechanism of RNA degradation using genetic engineering and molecular biology tools. His research also addresses harnessing photosynthesis for the production of electricity and hydrogen for the generation of green and clean energy. Gadi has published more than 100 publications in professional journals and book chapters.
He earned his bachelor’s degree (summa cum laude) from the Hebrew University of Jerusalem in 1982, and then continued for a PhD, obtained in 1988 from the same university. Gadi spent three years as a post-doctoral fellow at Berkeley, CA and then joined the Technion as an Assistant Professor in 1992. He served as the Executive Vice President for Academic Affairs of the Technion from 2012-2015, Dean of the Faculty of Biology from 2008-2012 and Vice Dean of the Jacobs Graduate School at the Technion from 2005-2008.
Gadi received several honors and prizes, including the best lecturer award twice. He served on numerous professional committees and is a frequent presenter at conferences and workshops. He is married to Dr. Ayelet Schuster, an ecologist, has two children, Meromit and Tal, and two grandchildren.
Prof. Manuel Trajtenberg
Prof. Manuel Trajtenberg was born in Argentina in 1950 (immigrated to Israel in 1966), is married to Dr. Nadine Baudot-Trajtenberg who serves as Deputy Governor of the Bank of Israel, and is the father of three daughters. He holds a BA and MA in Economics from The Hebrew University of Jerusalem and has a PhD from Harvard University. He is an economist by profession and a Professor of Economics at Tel Aviv University. His areas of academic expertise include the economics of technology and innovation, development and growth. Manuel is considered a world-renowned expert in these fields, serving as a member of research institutes in the United States and Europe, as well as on OECD advisory committees.
In 2006, Manuel set up the National Economic Council in the Prime Minister’s Office, which he headed until 2009. Between 2009 and 2014, Manuel chaired the Planning and Budgets Committee in the Council for Higher Education. Following the social protests in 2011, he was appointed Chair of the Government Committee for Social and Economic Change (the Trajtenberg Committee), spearheading, inter alia, extension of the Free Education Law to kindergarten-aged children. He was also a member of several public committees, including the Brodet Committee for the Defense Budget and the Shochat Government Committee for the Reform of Higher Education. He was also a member of the Israel Democracy Institute Executive Committee and the Scientific Advisory Board at RAFAEL during development of the Iron Dome defense system. He also served as economic advisor to ministers and chief scientists in the Ministry of Industry, Trade and Labor.
Manuel was elected to his maiden term in parliament for the 20th Knesset as member of the Zionist Camp. He serves as member of the Finance Committee; Education, Culture and Sports Committee; the Joint Committee for the Defense Budget and the Special Committee to Discuss the Motion for the Agenda on Difficulties in Reforming the Civil Service. He also chairs the Lobby for the Protection of Preschoolers in Israel; the Lobby for Growth Companies in Israel and the Lobby for the Creation of Opportunities for the Haredi Public in Israel. He is a member of the Lobby for Children and Youth at Risk; the Lobby for Development of the Arab Economy; the Lobby for Strengthening the Jewish World; the Lobby for Rare Diseases and Orphan Diseases; the Lobby for Fair Pension; the Lobby for Young Families; the Lobby for Jewish Renewal and Lobby for Narrowing Gaps in Education. He also chairs the Israel-Peru and Israel-Cyprus Parliamentary Friendship Groups.
Prof. Rachel Erhard
Prof. Rachel Erhard is Tel Aviv University President's Advisor of Gender Equity, and a Professor at the School of Education. Her work represents a unique combination of academia and intensive social activity in Israel and abroad. As the President's Advisor on Gender Equity, Rachel is working toward introducing institutional changes aimed at promoting gender equity; increasing rates of women in faculties and committees and of recipients of prizes, awards and grants. Rachel leads the strategic plan for implementing gender equity in Tel Aviv University, and developed unique career workshops for female PhD candidates. In addition, Rachel is the head of the Forum of the President's Advisors on Gender Equity for all research universities in Israel. Rachel held senior positions in the education system, most recently the Head of the Research and Development Unit at The Psychological and Counseling Service, Ministry of Education and Culture. She has published four books and dozens of articles and studies. As the head of Graduate Program of School Counselling, Rachel has helped shape and establish educational counselling as a profession in Israel. In her voluntary work, she is an active member of the Planned Parenthood Association, served as its Israeli VP and is on the accreditation committee of the European region.
Prof. Rivka Carmi
President of Ben-Gurion University of the Negev.
Professor Rivka Carmi was elected to serve as President of Ben-Gurion University of the Negev (BGU) by the University’s Board of Governors in May, 2006. She is the first woman to serve as president of an Israeli university.
Rivka was born in Israel and is a graduate of the Hadassah Medical School at the Hebrew University of Jerusalem. She completed a residency in pediatrics, a fellowship in neonatology at the Soroka University Medical Center and an additional two-year fellowship in medical genetics at Boston Children’s Hospital and Harvard University Medical School.
Rivka served as Director of the Genetics Institute at the Soroka University Medical Center and held several important academic administrative positions in the Faculty of Health Sciences at Ben-Gurion University of the Negev. Promoted to full professor in 1995, she is the incumbent of the Kreitman Foundation Chair in Pediatric Genetics. In 2000, she was elected Dean of the Faculty of Health Sciences at BGU – also the first woman to hold this position in Israel – and served in that position for five years. In 2002 – 2005, she served as the Chair of the Israeli Association of Medical Deans.
Prior to entering the University’s administrative arena, Rivka’s research focused mainly on the delineation of the clinical manifestations and molecular basis of genetic diseases in the Negev Arab-Bedouin population. Author of over 150 publications in medical genetics, her research includes the Identification of 12 new genes and the delineation of 3 new syndromes, one of which is known as the Carmi Syndrome. Her community projects were aimed at preventing hereditary diseases in the Bedouin community. She was deeply involved with the establishment of major biotechnology initiatives at Ben-Gurion University of the Negev, primarily serving as the Acting Director of the nascent National Institute for Biotechnology in the Negev.
In addition to her duties as President, Rivka remains a member and serves as a consultant of national, professional and public committees and organizations, is a scientific reviewer for various international journals and funding agencies and serves on the editorial board of prestigious scientific journals. Recent noteworthy honors she has received include: the Lifetime Achievement Award by the Yated organization for children with Downs Syndrome; the Achievement in Medicine Award by the Municipality of Beer Sheva; the 2002 Award for Peace from the Canada International Scientific Exchange Program (CISEPO), to which she served as representative of the Israeli Medical Deans; the 2008 Women of Distinction Award of the Hadassah Women’s Zionist Organization of America; and in 2009, an Award of Excellence from the Israel Ambulatory Pediatric Association (IAPA). In 2013 she received an Honorary Doctorate from Dalhousie University in Halifax, Nova Scotia.
In August 2010, Rivka became the first woman to serve as the Chair of the Committee of University Heads in Israel. She served in this role until December 2012.
In June 2015, Rivka received an honorary Commander of the British Empire (CBE) in the name of Queen Elizabeth II.
Dr. Yaron Daniely
Dr. Yaron Daniely has been the President and Chief Executive Officer and a Director of Alcobra Ltd, since March 2010. Immediately prior to joining Alcobra and since 2007, Dr. Daniely was the President and Chief Executive Officer of NanoCyte, Inc., a company that develops transdermal delivery technologies based in Caesarea, Israel. Before NanoCyte and from 2004, Dr. Daniely was the General Manager of Gamida Cell—Teva Joint Venture Ltd., a joint venture company that acquired an exclusive license to develop and commercialize a Phase 3-stage cell therapy product for treatment of Leukemia and Lymphoma based in Jerusalem, Israel. From 2003-2007, Dr. Daniely also served as the Vice President of Business Development of Gamida Cell Ltd., and engaged in several licensing and financial transactions for the Company. In addition, he co-founded and served as a director of Bioblast Ltd. (NASADQ:ORPN). Dr. Daniely holds a B.Sc. degree in Biological Sciences from Florida International University, and holds a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine. Following his doctoral program, Dr. Daniely served as an NIH Visiting Fellow in its Cell Biology section and a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Subsequently, he received an Executive M.B.A. from the Technion, Israel Institute of Technology. Dr. Daniely co-founded Israel’s first M.B.A. program specializing in Biomedical Management at the College of Management Academic Studies (Rishon Letzion, Israel) and has served as the program’s director since its inception
Dr. Dov Tamarkin
Dr. Dov Tamarkin is a senior pharmaceutical executive, with over thirty years of experience. Between 2013 and 2017 he was Chief Executive Officer of Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX). Prior to Foamix, Dr. Tamarkin held multiple executive positions at Teva Pharmaceuticals, Portman Pharmaceutical Industries, PowerPaper and TPI. He holds a Ph.D. degree in organic chemistry from The Hebrew University of Jerusalem, Israel; and he is the inventor of over a hundred patents in the pharmaceutical field.
Prof. Zvi Livneh
Dean, Faculty of Biochemistry
Director, Swiss Society Institute for Cancer Prevention Research
Prof. Zvi Livneh earned his BSc in chemistry from Tel Aviv University in 1971, and his PhD from the Weizmann Institute in 1980. He completed postdoctoral studies in the Department of Biochemistry at Stanford University’s School of Medicine in Palo Alto, California. In 1984, he joined the staff of the Weizmann Institute’s Department of Biochemistry, which he headed from 1993 to 1997. He headed the Weizmann Institute’s Department of Biological Chemistry, now the Department of Biomolecular Sciences, from 2002 to 2007 and has served as Dean of the Faculty of Biochemistry since 2010. He is the incumbent of the Maxwell Ellis Professorial Chair in Biomedical Research.
Prof. Livneh’s research focuses on the mechanisms by which our cells repair the DNA from the more than 50,000 daily “attacks” on genetic material in our bodies, caused by sunlight, tobacco smoke, metabolic byproducts, and other environmental agents. The DNA repair system, based on enzymes, is essential for protecting genes from incorporating disease-causing mutations, particularly cancerous ones. Indeed, mutations in the DNA repair system are implicated in many hereditary cancers. Prof. Livneh discovered an enzyme called error-prone DNA polymerase, the culprit in a rare type of skin cancer. He also discovered, together with Dr. Tamar Paz-Elizur, that in humans, a weak DNA repair score, determined by measuring the activity of a panel of three DNA repair enzymes called OGG1, MPG and APE1, is a strong risk factor for lung cancer. He and his colleagues are further developing this panel of DNA repair biomarkers to assist physicians in the risk assessment and early detection of lung cancer.
Prof. Livneh is the recipient of numerous awards, including the Sergio Lombroso Award in Cancer Research (2013/2014), the Israel Sarov Memorial Prize, awarded by the Israel Society for Microbiology (2002), ), the Weizmann Institute’s Morris Levinson Prize (1995), and a Yigal Alon Scholarship (1986-1989).
He likes reading, the performing arts, hiking, and delivering popular scientific lectures in an effort to narrow the gap between the frontiers of science and the public.
Dr. Amir Bahar
Co-Founder & CEO of Nurami Medical.
Dr. Amir Bahar is a graduate of the Weizmann Institute of Science and a veteran of Mount Sinai Medical Center in New York and the Technion.
Amir completed his PhD in neurobiology and brain research at the Weizmann Institute in 2004. His thesis focused on the biochemical and neurophysiological aspects of learning. He later completed a postdoc in neurophysiology of learning at the Mt Sinai Medical School, NY. In parallel, he served as BioAbroad's regional manager. He returned to Israel in 2011 to pursue a career in the biomedical industry. In 2013 he co-founded a medical device company that develops smart nanofibers for the surgical field. The company has been active in the Chief-Scientist’s incubator in Nazareth since April 2014.
Dr. Noam Shomron
Lecturer and Principal Investigator (PI), Faculty of Medicine, Tel Aviv University.
Dr. Noam Shomron received his BA in Biotechnology from the Macquarie University in Sydney, Australia; his MA in Gene Therapy at The Hebrew University of Jerusalem; and a PhD in Genetics from Tel Aviv University where he worked on regulatory RNA systems. As a postdoctoral affiliate at MIT in Cambridge, USA, Noam specialized in combining high-throughput data with computational analysis to decipher gene regulation in health and diseases. Today, Noam heads the Functional Genomics Laboratory at Tel Aviv University’s Medical School, and serves as the Editor-in-Chief of Genetics Research, a Cambridge University Press Journal. Noam’s team explores regulation of gene expression mainly by small RNAs, and aspires to reach a global systems’ view of the mechanistic roles they play in health and diseases.
Dr. Natalie Artzi
Dr. Natalie Artzi is an Assistant Professor at the Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School. She is a Principal Research Scientist at MIT and an Associate Member of the Broad Institute of Harvard and MIT.
She completed her postdoctoral studies Prof. Elazer Edelman’s lab at MIT, focusing on smart biomaterials design.
Natalie pioneered basic research in the areas of tissue adhesive materials and tissue: material interactions. She completed her PhD under the mentorship of Prof. Moshe Narkis at the Department of Chemical Engineering at the Technion, Israel Institute of Technology. Her PhD focused on the development of Polymers: Clay Nanocomposite Systems.
Natalie directs multiple research venues aiming to integrate science, engineering and medicine to solve problems in human health. Her tissue-responsive nanomaterials research is dedicated to rationally designing personalized materials and medical devices to combat cancer, improve tissue regeneration in orthopedic applications and treat gastrointestinal diseases.
She was a member of the Scientific Advisory Board of Science Translational Medicine, the Program Committee of the American Society for Biomaterials, as well as editorial boards and advisory boards of biotech companies. Aiming to propel technologies from bench to bedside, the group studies tissue: biomaterial interactions in light of clinically-relevant conditions as manifest by the disease. Natalie recently founded her first spin off company from her lab, which provides solutions for better wound closure and healing following internal surgeries.
Dr. Dov Reichman
Dr. Dov Reichman has been a senior manager in the fields of R&D, innovation and entrepreneurship, and international marketing and business development for than 25 years.
He is the owner and CEO of Spectra-Analytics, which consults companies, investors, and entrepreneurs in the areas of technological innovation, and traditional industry, services, and investments.
He was formerly CEO in chemical and diagnostics companies, VP of commercialization of technologies and patents in applied chemistry and physics at The Hebrew University of Jerusalem, and Marketing and Sales Manager in the multi-national Sigma Aldrich Company (NASDAQ: SIAL).
Dov’s technological expertise is in the fields of chemistry, advanced materials, nanotechnology, green industries, and security technologies. Dov has a PhD in chemistry from The Hebrew University in Jerusalem and his research earned the Israeli President’s Award for two consecutive years.
Prof. Karen B. Avraham
Prof. Karen Avraham’s research has centered on the discovery of disease genes, focusing on
hereditary hearing loss. Her team takes a comprehensive approach to studying the molecular basis of hearing loss, using genetic, developmental, biochemical, cellular and bioinformatic tools. She leads efforts in next-generation sequencing for the discovery of disease genes that are relevant for the Israeli Jewish and Palestinian Arab hearing impaired population. Her group has demonstrated that non-coding RNAs - microRNAs, are essential for the development and functioning of inner ear hair cells in vertebrae.
Mrs. Malka Lion
prof. gad barzilai
Gad Barzilai is a professor of law, political science and international studies, known
for his work on the politics of law, comparative law and politics, human rights and
Prof. Barzilai published 18 books, some of which are award-winning, and 173 articles
in major academic journals and publishing houses. Over the course of his career, prof.
Barzilai has been teaching at the University of Washington in the USA, and the Tel
Aviv University. Prof. Barzilai served as the Dean of the Faculty of Law at
the University of Haifa (2012 - 2017).
Prof. Barzilai is currently serving as a Vice-Provost and the Head of the International
School at the University of Haifa.
Dr. Sara Eyal
Dr. Sara Eyal was born and raised in Tel Aviv.
Her interest in drug research was roused during high school at youth science camps. Following her military service, she completed undergraduate studies at the Faculty of Agriculture at Tel Aviv University, continuing her MA at the Department of Physiology and Pharmacology at Tel Aviv University, under the tutelage of Prof. Moshe Rehavi. Upon completion, Sara began a pharmacy degree at the School of Pharmacy at The Hebrew University of Jerusalem and specialized in pharmaceuticals and internal medicine at Assaf Harofeh Medical Center. She then completed graduate studies in Clinical Pharmacy. Her MA research was guided by Professors Amnon Hoffman and Michael Friedman and focused on the development and characterization of a gastroretentive dosage form of levodopa. Sara received her degree Summa Cum Laude in 2002 and continued her studies in the laboratories of Professors Meir Bialer and Boris Yagen toward her PhD. Her work focused on the mechanisms of pharmacokinetic resistance to antiepileptic drugs, which occurs in about 30% of patients with epilepsy. One of its findings saw the antiepileptic drug, valproic acid, and some of its derivatives, increase the expression and activity of P-glycoprotein, an efflux transporter which removes drugs from cells, contributing to the pharmacokinetics of many drugs and to multidrug resistance in cancer cells. Results of her research were published in Epilepsia, the British Journal of Pharmacology and Biochemical Pharmacology.
Prof. Jerry Eichler
Prof. Jerry Eichler received his BSc (Physiology, 1982) from McGill University in Montreal, Canada, and his M.Sc. (Neurobiology, 1988) and PhD (Neurobiology, 1994) from the Weizmann Institute of Science in Rehovot, Israel. He was a Postdoctoral Fellow (1994 to 1998) in the Department of Biochemistry at the Dartmouth Medical School in Hanover, NH. Since 1998, Jerry has served as a Professor in the Department of Life Sciences at Ben-Gurion University of the Negev. His research addresses N-glycosylation and other post-translational modifications in Archaea.
Dr. Iris Grossman
Vice President, Head of Personalized & Predictive Medicine and Analytics Big Data, Teva.
Dr. Iris Grossman, VP, Global Head of the Personalized & Predictive Medicine and Analytics Big Data (PPM-ABD) unit for Teva Global R&D, has dedicated her research career (industry and academia) to the advancement of personalized medicine. She is currently charged with defining and implementing the global PPM-ABD strategy for Teva R&D, a leading global pharmaceutical company, covering discovery development and repurposing programs. In 2013, Globes Magazine - Israel’s leading financial magazine, coined Dr. Grossman one of Israel’s top 40 professionals under the age of 40 .
Prior to joining Teva, Dr. Grossman was CEO and president of the pharmacogenetics management consultancy IsraGene Ltd., providing services to both the pharma and biotech sectors. This followed several years of spearheading pipeline pharmacogenetic programs for industry and academia as director of pharmacogenetics at Cabernet Pharmaceuticals Inc. Dr. Grossman moved into consultancy having been responsible for running large-scale pharmacogenetic programs at GlaxoSmithKline, with an emphasis on infectious and neurological diseases.
In academia, Dr. Grossman was a key member of Professor David Goldstein’s team at the Center for Population Genomics and Pharmacogenetics, Institute for Genome Sciences and Policy, at Duke University. Dr. Grossman received her PhD from the Technion – Israel Institute of Technology, where her research project, conducted in collaboration with the Weizmann Institute for Science, investigated pharmacogenetic markers of multiple sclerosis treatment response.
Prof. Shira Hantman
Prof. Shira Hantman has more than 40 years’ experience in the field of gerontology. She is currently Vice President for Academic Affairs at Tel Hai College in the Upper Galilee, Israel. She also chairs several committees in the field of Aging, among them the Gerontology Accreditation Committee at Israel’s National Association of Social Workers and member of the Ministry of Welfare's Committee for community services. Shira authored the book "The Sandwich Generation" and has published extensively in the field of gerontology, specifically on the topics of intergenerational family relationships, trauma, Holocaust survivors, aging and forgiveness and entrepreneurship of older adults.
Dr. Neta Kela
CGA (immunotherapy) Omni Consulting (innovative technologies).
Dr. Neta Kela, PhD, is a business development professional in the field of innovative technologies in the healthcare and biotechnology industries. Neta is the Co-Founder of CGA, an automated CAR-T manufacturing device company and the Founder and CEO of Omni, an international business development and scientific consulting firm specializing in precision medicine, cell therapy and immunomodulation. Neta graduated with a PhD from the Weizmann Institute, focusing on clinical research and auto-immune disorders. Following her PhD, Neta was a postdoc fellow at Stanford University, CA, USA, focusing on clinical oncology research and won the McCormick Award from Stanford University, School of Medicine. Neta is a senior faculty member at the Peres Academic Center for Innovation and Entrepreneurship and a lecturer at the Ben-Gurion MBA Executive Program.
Prof. Masha Niv
Associate Professor, Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, Rehovot, The Hebrew University of Jerusalem.
Prof. Masha Niv’s lab studies molecular recognition of taste and smell compounds using atomistic computational methods as well as sensory evaluation and in-vitro techniques. Masha graduated cum laude in Chemistry in 1994 and continued directly into PhD in theoretical chemistry, graduating in 2001 from the Hebrew University. She worked as a bioinformatician and group leader at Keryx Pharmaceutical before her postdoctoral position at the Weill Medical College of Cornell University, NY. Masha established her lab at the Robert H. Smith Faculty of Agriculture, Food and Environment at the Hebrew University, Rehovot, in 2007. Masha is passionate about promoting scientific careers for young scientists, and specifically women in science.
Prof. Shulamit Michaeli
Associate Professor, Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, Rehovot, The Hebrew University of Jerusalem.
Faculty of Life Sciences and Institute for Nanotechnology and Advanced Materials, Bar-Ilan University.
Prof. Shulamit Michaeli is a member of the Mina and Everard Goodman Faculty of Life Sciences and the Nano Medicine Center at the Institute of Nanotechnology and Advanced Materials (BINA). She is an expert on silencing RNA – designing and synthesizing RNA-protein complexes that inhibit the functioning of a variety of genes from human parasites to man.
A mission-oriented entrepreneur with track record performing senior executive roles in the Israeli High Technology scene.
Currently serving as CEO and Co-founder of BeaconCure, a startup with developing an AI text analytics technology for clinical data.
Yoran also serves as the founding Director of 'The HAC', a successful Urban Accelerator in Israel, where I serve as a member of the advisory board supporting the organization and its young entrepreneurs as a pro bono project.
Yoran also acts as Israel Country Adviser for the US-based ‘International Accelerator’ from Austin Texas and, as an International Adviser for 'TechGrind' an Asian Accelerator based in Bangkok, Thailand.
Yoran spent a few years in West Europe serving multinationals such as Adidas and HP in the development of data-centric systems while resided in Amsterdam, The Netherlands.
Yoran completed his MBA from the University of Den Haag and owns a BA in Psychology & Communications from the University of South Africa.
Head of Government Affairs and Policy, Corporate HQ & Growth Markets Teva Pharmaceutical Industries Ltd.
Mati is the Head of Government Affairs and Policy for Corporate HQ and Growth Markets at Teva Pharmaceutical Industries, a global leader in generic and specialty pharmaceuticals that delivers high-quality medicines to 200 million people around the world every day. Mati previously served as Chief Operations Officer (COO) of the Teva Global Legal Group between 2011-2016 and serves as a member of the Board of Directors of Sanara Ventures.
He is also a licensed Lawyer and served as the Executive Director of the Australian Israel Leadership Forum. Until March 2009, Mati served as Chief of Staff of Israel's Minister of Public Security Mr. Avi Dichter, a position in which he was in charge of management of the Minister's public agenda and office, and advised on professional, political, communications and international affairs.
Mati is an active social entrepreneur in the Israeli community. He co-founded and leads the "Sanhedrin Forum" for young Israeli professionals. A reserve officer at the rank of Major in the IDF, Mati served as Operational Liaison Officer with United Nations Peacekeeping Forces in Lebanon and the Golan Heights and with the United States Army.
Prof. Roy Kishony
Marilyn and Henry Taub Professor of Life Sciences, Faculty of Biology, Faculty of Computer Science (secondary), Technion - Israel Institute of Technology
Visiting Faculty - Department of Systems Biology, Harvard Medical School.
Prof. Roy Kishony is the Marilyn and Henry Taub Professor of Life Sciences at the Technion-Israel Institute of Technology, Director of the Technion’s Lorry Lokey Center for Life Sciences and Engineering and a Visiting Faculty Member at the Department of Systems Biology at Harvard Medical School. Roy received his BA in Physics and Mathematics from The Hebrew University of Jerusalem and his PhD in Physics from Tel Aviv University (1999). He transferred to Biology in his postdoc at Princeton and Rockefeller Universities. In 2003, he started an independent laboratory at Harvard University, first as a Bauer Fellow and then as a member of the newly established Department of Systems Biology at the Harvard Medical School, where he was quickly promoted to a Full Professor. As a physicist at a major medical school, Roy became fascinated by the urgent public health concern over the rapid evolution of antibiotic resistance.
His combined theoretical-experimental background enabled him to define key questions in evolution of resistance in bold new ways. His lab has made a series of ground-breaking discoveries, showing how some drug interactions can select against resistance, unraveling mechanisms that keep resistance in check in natural ecological environments, and pioneered unique experimental and theoretical methodologies for tracking whole-genome evolution of pathogenic bacteria. These new approaches and discoveries inspire novel treatment paradigms for effective antimicrobial chemotherapy and genome-based diagnostics.
Roy received the Genzyme award for outstanding achievements in biomedical sciences (2009), a Gates Foundation Grand Challenge Award (2008), a Complex Systems award from the McDonnell Foundation (2008), the Sanofi-Pasteur award (2013) for “establishing the quantitative principles governing evolution of resistance in multi-drug treatments, creating a new discipline at the intersection of pharmacology, systems biology, and evolution”. He has been elected as a member of the Israeli Young Academy (2016), and as a member of EMBO (2017). His research has attracted significant attention, was featured at the United Nations and has been covered in the international media, including CNN, NPR, WIRED, Wall Street Journal, Boston Globe, Scientific American, Nature News, 60-Minutes Australia and the UK’s BBC.
Dr. Michal Zalzman
Assistant Professor in the Department of Biochemistry and Molecular Biology, with a secondary appointment in the Department of Otolaryngology, Head and Neck Surgery at the University of Maryland, Baltimore.
Dr. Michal Zalzman has been a molecular cell biologist and an established stem-cells expert since 2000. She received her BSc from the University of Bar Ilan, Israel, MSc and PhD from Tel Aviv University, Israel, in the Department of Human Molecular Genetics and Biochemistry. She then completed postdoctoral work at the National Institute of Aging/NIH, in the Developmental Genomics and Aging Section in the Laboratory of Genetics. She holds multiple worldwide patents from WIPO.
Michal’s lab focuses on novel fundamental mechanisms controlling cellular immortality. Her team studies cellular immortality and telomere repair in two major systems: adult stem cells and cancer cells. Their goal is to characterize the components of a novel apparatus that allow cancer to bypass cell aging in order to ultimately allow the development of a new class of agents designed to target cancer immortality. The lab has also generated adult stem cell lines from multiple tissue sources. The teams develops novel protocols to enhance the replicative lifespan and the differentiation potential of adult stem cells. This research will allow the large scale expansion of adult stem cells required for future therapies of numerous diseases that are currently candidates for stem cell treatment.
Dr. Nurit Eyal
Dr. Nurit Eyal holds a PhD from the Weizmann Institute of Science, Department of Chemical Immunology. She is a serial entrepreneur, who founded a number of biotechnology startups in different fields including molecular diagnostics of genetic diseases and cancer, new vaccines and innovative drugs and published several patents. Nurit served as Head of Life Science Investments at Pamot VC and Yozma VC and was a business development consultant for international companies as well as Israeli companies in the life sciences field. She is the Co-Founder and First Director of the Israel Brain Gain National Program. She has been an independent consultant since April, 2017.
Position: Senior Program Director
Position: Director of Operations